Pfiz­er/Mer­ck KGaA launch sol­id tu­mor com­bo study with Leap; As­traZeneca and Im­munomedics to test ADC can­cer com­bo

→ Pfiz­er and Mer­ck KGaA are team­ing up with Leap Ther­a­peu­tics $LP­TX to eval­u­ate the small Cam­bridge, MA-based com­pa­ny’s drug in a com­bo with Baven­cio (avelum­ab) and chemo. Leap is de­vel­op­ing a drug called TRX518, a hu­man­ized mon­o­clon­al an­ti­body that binds to the glu­co­cor­ti­coid-in­ducible TNF-su­per­fam­i­ly re­cep­tor. It’s be­lieved to boost the body’s an­ti-tu­mor re­sponse, and will be test­ed in this com­bo in pa­tients with sol­id tu­mors. Un­der the terms of the deal, Leap will con­duct a Phase I/II study, with en­roll­ment start­ing in Q1 2019.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER